
NICE has recommended three new treatment options for hepatitis C in draft guidance – but has been criticised for excluding …

AbbVie has been handed a boost by NHS England, who has approved the prescribing of its Parkinson’s disease treatment Duodopa …

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended several treatments for marketing …

AstraZeneca, Genentech and AbbVie have all revealed which cancer drugs they will show data for at The American Society of …

In a Phase III trial AbbVie’s anti-inflammatory medicine Humira has been shown to significantly lower the risk of uncontrolled uveitis …

AbbVie’s combination hepatitis C treatment looks set to be approved in yet another country after being granted priority review in …

US giant Pfizer spends far more on direct-to-consumer advertising than any other pharma firm according to new data from Kantar …

Ten firms will partner up with Genomics England to develop new diagnostics and treatments for people with rare diseases and …

AbbVie is investing $30 million to expand one of its sites in Puerto Rico, and is also backing a promising …

AbbVie has secured Californian biotech Pharmacyclics and beat Johnson & Johnson to gain control of blockbuster blood cancer therapy Imbruvica in …

Shire has purchased Meritage Pharma, a privately-held company specialising in gastrointestinal and skin diseases for $70 million. The acquisition means …

Merck is teaming up with the Medicines Patent Pool (MPP) to license its paediatric HIV treatment in developing countries. The …

Shire has posted strong growth in its full-year results, showing that the company is faring well even after the collapse …

The European Commission has approved AbbVie’s Viekirax and Exviera for the treatment of chronic hepatitis C (HCV). Viekirax (ombitasvir/paritaprevir/ritonavir) and …